Hirohisa Yano

TL;DR: There is an urgent need for a new comprehensive treatment strategy combining antiangiogenic agents with conventional cytoreductive treatments in the control of cancer.

TL;DR: Vascular endothelial growth factor expression immunohistochemically in hepatocellular carcinomas (HCCs) in various histological grades and sizes indicates that various cytokines and growth factors could cooperatively act to enhance VEGF expressions in HCC.

TL;DR: It is shown that sequential self-assembly of the EGCG derivative with anticancer proteins forms stable micellar nanocomplexes (MNCs), which have greater anticancer effects in vitro and in vivo than the free protein.

TL;DR: Muc‐ICCs had a clinicopathological, immunohistochemical, and molecular profile similar to that of hilar CCs (from mucin‐producing cholangiocytes), whereas mixed‐ICC had a profile similarto that of CLCs (thought to be of HPC origin), possibly reflecting their respective cells of origin.

TL;DR: Morphological, DNA, and cell cycle analyses revealed two possible modes of action of sho-saiko-to to suppress the proliferation of carcinoma cells; it induces apoptosis in the early period of exposure and it induces arrest at the G0/G1 phase in the late period of Exposure.